Date of event: estimated date.
The udi number is "ni" as the part number was not provided.
The device is not returning for evaluation.
Investigation is not yet complete.
A follow-up report will be submitted with all additional relevant information.
The additional patient effects, malfunctions, and devices referenced in the report are captured under separate medwatch report numbers.
Literature titled ¿post market clinical follow-up evaluation report peripheral dilatation catheter family¿.
|
The post-market clinical follow-up (pmcf) report, titled ¿post market clinical follow-up evaluation report peripheral dilatation catheter family¿ evaluated the safety and performance of the viatrac 14 plus, armada 14, armada 14xt, armada 18, armada 35, and the armada 35 ll.
It was reported through a pmcf report that the armada 35 ll may be related to unsuccessful dilatation of a vessel, stent, and/or chronic total occlusion, unsuccessful delivery, inflation, and/or deflation, embolism, dissection, perforation, total occlusion, abrupt closure, arrhythmia, renal failure, thrombosis, occlusion, venous hypertension, pseudoaneurysm, hematoma, and hemorrhagic events.
Although the above events were noted, in conclusion, the overall analyses from this study demonstrates that the use of the abbott dilatation catheters met the safety and performance criteria and perform similarly to competitive state of the art devices.
|